


MSTS Newsletter

Volume 30, Fall 2022

Inside this Issue

President's Report	1	Musculoskeletal Tumor Registry	6	Fellowship Committee	10
Treasurer's Report	2	Guidelines and EBM Committee	6	Metastatic Bone Disease Task Force ...	10
MSTS Executive Committee	2	Thank You Donors!	8	Update from NOLC, BOS/BOC	12
2023 Specialty Day	4	Membership Committee	8	SarcomaStrong Corner	12

President's Report – Michael P. Mott, MD



Michael P. Mott, MD

It has been a productive year for the Musculoskeletal Tumor Society, and I am happy to report we remain a fiscally sound, independent, self-managed surgical sub-specialty society with our own office and management team. Please note, your society remains involved as a leader across all avenues within the spectrum of Orthopaedic Oncology. Examples include the AAOS Specialty Day in Chicago in March which was a tremendous success. We are indebted to the Specialty Day Program Committee for putting out a terrific program where we gave an ode to our mentors and those with outstanding careers, engaged in lively debate in areas of controversy and made an appraisal of our field's potential future. Additionally, the Education Committee instilled their tumor knowledge to the AAOS with excellent presentations and instructional course lectures.

After the AAOS, the Executive Committee rolled up their sleeves to engage in the business of the Society. The Metastatic Bone Disease Task Force became empowered and given shape. A call for volunteers was made. Dr. Wodajo, as chair,

will update their progress during the annual meeting. Our Fellowship Committee successfully ran the match for accredited Orthopaedic Oncology Fellowships this year. Lastly, the EC is actively engaged in updating our strategic plan.

As summer faded, our attention turned to the Annual Meeting at the Wyndham Grand at Clearwater Beach, Florida, November 30 to December 2, 2022. The Annual Meeting committee has made every effort to provide what we hope will be a phenomenal interactive event with ample time to engage, learn, debate, and collaborate with each other both professionally and socially, as well as with our allied health and industry partners. The meeting starts out with an in-person coding course done in conjunction with the Practice Management committee. Annual Meeting Program Chair, Tessa Balach has packed the meeting with excellent scientific

papers and posters from our members.

Our presidential guest speaker is the renowned Dr. Robert Gatenby, MD from Moffitt Cancer Center in Tampa who will be offer-

Continued on page 2



MSTS Headquarters

1515 E. Woodfield Road, Suite 345

Schaumburg, IL 60173

info@msts.org

847/698-1625

President's Report, cont'd from pg. 1

ing his unique perspective on cancer and cancer management with his talk entitled "Harnessing evolutionary dynamics for control and cure of metastatic cancers." For those able to stay Friday afternoon, there will be a musculoskeletal ultrasound course taught by internationally known radiologists with an emphasis on performing ultrasound guided biopsies.

Social events include the welcome reception on the patio / pool deck of our hotel with direct vision of fabulous Gulf of Mexico sunsets and the beach. Our signature dinner/ social event will be held at the Island Way Grill just a short distance from the hotel. An enjoyable collegial evening of excellent food, relaxation, and music is anticipated. All are invited to this event.

Lastly, the exhibitor's room should be lively and engaging with twenty-one sponsors. Our diamond level industry partners are providing five Product Theaters and I would strongly encourage attendance for updates on the latest technology. Our industry partners are vitally important in hosting our Annual Meeting and in meeting the goals and mission of our Society. Many thanks to our diamond level partners: Daiichi Sankyo, Inc., Medtronic,

Onkos Surgical, Springworks Therapeutics and Zimmer Biomet.

Certainly, it would be impossible to not note Hurricane Ian's devastation in Florida. We have been in contact with our venues and the Clearwater Beach area did NOT suffer notable storm damage. Perusing the internet reveals hurricane season runs until November 30. Our management is engaged in making sure mother nature is aware of the calendar.

As my year closes out, I am humbled to have had this opportunity to serve this fantastic organization and represent our profession as the President of the MSTs. I would like to give heartfelt thanks to all committee members, committee chairs, and presidential line members. I would also like to thank our management team Kerri Mink and Deborah Meyer for keeping us on track on all things. I could not have done anything without everyone pitching in when asked.

Mike
Cell: 313-671-1873
Email: mmott2@hfhs.org

Treasurer's Report – Rajiv Rajani, MD


Greetings MSTs Membership. Similar to many individuals' financial situation, our society has seen negative net changes since the last report. Fortunately, our society has had a cushion of growth and financial stability that has not adversely affected our ability to support new programs while maintaining the quality of our prior endeavors. Having emerged from the COVID pandemic, geopolitical unrest, and relative stagnation in markets, our investment portfolio has remained relatively consistent with benchmarked accounts. We also saw unprecedented gains during the COVID pandemic in our investments accounts which left us with a healthy balance to work from.

As you know, membership dues are a critical part of our predictable revenue stream, and necessary to be able to provide administrative support, stability, and overall function to the organization. We thank all

Continued on page 4

Are You Registered?

Details and online registration for the MSTs 2022 Annual Meeting can be found [here](#).
Register today!



MSTS Executive Committee

President

Michael P. Mott, MD
mmott2@hfhs.org

President-Elect

Michelle Ghert, MD
ghertm@mcmaster.ca

Secretary

Benjamin Miller, MD
benjamin-j-miller@uiowa.edu

Treasurer

Rajiv Rajani, MD
rrajani@ttuhsc.edu

Immediate Past President

Carol D. Morris, MD
morrisc@mskcc.org

Past President

R. Lor Randall, MD, FACS
rlrandall@ucdavis.edu

Education Committee

Wakenda K. Tyler, MD
wkt2106@cumc.columbia.edu

Research Committee

Kurt Weiss, MD
weiskr@upmc.edu

Membership Committee

Matthew R. DiCaprio MD
mdicaprio15@gmail.com

Members-at-Large


Megan Anderson, MD
Megan.Anderson@childrens.harvard.edu

Melissa Zimel, MD
melissa.zimel@ucsf.edu

MSTS 2022 ANNUAL MEETING ACKNOWLEDGMENTS

THANK YOU

The Musculoskeletal Tumor Society extends sincere appreciation to the following exhibitors for their generous support of the MSTS 2022 Annual Meeting.



DIAMOND EXHIBITORS



Medtronic



BRONZE EXHIBITORS

LinkBio Corp
Merete Technologies, Inc.
OsteoCentric Technologies
Stryker

AAOS Musculoskeletal Tumor Registry (MsTR)
Advanced Recovery Specialists
Austin Medical Ventures
Avitus Orthopaedics
Biocomposites
BoneSupport, Inc.
Carbofix Orthopedics, Inc

Deciphera Pharmaceuticals
IlluminOss Medical
Implantcast North America
Integrum, Inc.
MTF Biologics
Vector Surgical

the members who have continued to commit to the MSTs and encourage you to stay up to date on due payments.

Despite Hurricane Ian impacting the gulf coast of Florida, the plan is to continue our annual meeting in Clearwater, FL. It looks to be a stellar meeting with much thanks to Austin Medical Ventures, BoneSupport, Inc., Biocomposites, Carbo Fix Orthopaedics, Inc., Daiichi Sankyo, Inc., Integrum, Advanced Recovery, Vector Surgical, Avitus, SpringWorks Therapeutics, Inc.,

OsteoCentric Technologies Illuminos, Implantcast, LinkBio Corp, Medtronic, Merete Technologies, Inc., MTF Biologics, Onkos Surgical, Stryker, and Zimmer Biomet. This year, we have 6 new industry sponsors and I strongly encourage membership to visit their booths at the Annual Meeting as the commitment of industry to our Society has been imperative in maintaining the mission of the MSTs. Of course, any financial update wouldn't be complete without thanking Matt DiCaprio for his contributions to the Sarcoma

Strong organization. With new races being held in El Paso and Boston, the charitable contributions have increased both in number and scale. Thank you again Matt for making this possible.

I would like to thank the members of the Finance Committee, Danny Lerman, Christian Ogilvie, and Dieter Lindskog for their insight and assistance. Finally, thanks and recognition to Kerri Mink and Deborah Meyer for their help with the finances and management of the MSTs.

2023 MSTs Specialty Day – by Santiago A. Lozano Calderón, MD, PhD

The 2023 MSTs Specialty Day will be taking place in Las Vegas, Nevada Saturday March 11th, 2023. The program for this year was developed under the team effort and leadership of Panayiotis Papagelopoulos, MD as member at large, Luke Nystrom, MD as the Vice Chair and I, Santiago Lozano Calderón, MD, PhD as the Chair.

A series of presentations and discussion sessions have been organized to cover different topics of clinical and research interests relevant to the members of our society. Emphasis in new surgical techniques, technological advances, and new fields relevant to research advancements in orthopaedic oncology will be at the core of each of these sessions.

Attendees will have the opportunity to see experts discussing different approaches to challenges faced by the orthopaedic oncologist in shoulder reconstruction, functional ablative surgery and new technologies for intraoperative margin assessment in soft tissues sarcomas among other topics of interest. Speakers from other medical and surgical specialties will be joining to enrich the academic sessions during the day and keep the multidisciplinary spirit of our specialty. We will be bringing back our "Unknown Cases" competition and presentations of "my most challenging case"

To conclude, I want to thank Mrs. Deborah Meyer and Mrs. Kerri Mink for all their invaluable help and support. It was a pleasure to work side to side and collaborate



with Luke and Panayiotis. Their support and creativity has been invaluable for the planning of this session.

I look forward to seeing you participating in March 2023.

What Could **LESS TUMOR** Mean For Your Patients?

Learn more at our upcoming product theater on
Friday, December 2 from 9:50 AM -10:10 AM ET

**A unique approach to treatment in
symptomatic tenosynovial giant
cell tumor (TGCT)/pigmented
villanodular synovitis (PVNS)**

Presented by:

Thomas Scharschmidt, MD, MBOE, FAOA, FACS

Professor, Department of Orthopedics

The Ohio State University

Director, Pediatric Orthopedic Oncology

Nationwide Children's Hospital

Columbus, OH

Musculoskeletal Tumor Registry Update – by Benjamin Miller, MD, MS

The Musculoskeletal Tumor Registry (MsTR) has now contracted with 27 institutions. We continue to make steady progress toward a functional and searchable database, and the registry should be collecting data from 3-4 hospitals by the end of the year! We look forward to updating everyone at the annual meeting. Be sure to come by the booth to play around with the functionality of the dashboards and talk to members of the AAOS administrative team and steering committee members.

Under the guidance of Adam Levin, last year saw the publishing of our first Annual Report Preview. Adam and his team submitted abstracts that were presented at ISOLS, MSTs, and CTOS in 2022. Nate Mesko serves as the lead for the Data

Elements Subcommittee and has worked to finalize the collection instruments for the sarcoma and metastatic disease of bone modules. Eric Henderson has been thinking about long-term applications of the registry and is exploring grant funding opportunities to help add functionality and explore its capabilities. Additional Steering Committee members John Alexander, Megan Anderson, George Calvert, Mark Scarborough, and Kristy Weber have worked on this and other projects diligently since the group was formed last year. Joe Schwab has been designated as the liaison to the spine tumor module with the American Spine Registry.

Another priority of the MsTR is to continue working with David Greenberg and his OREF-sponsored randomized controlled

trial in giant cell tumor of bone. We are working with his team to explore the use of the MsTR as a data collection instrument for this and future clinical trials. Our hope is that the lessons learned with this project will inform how the registry may be used to facilitate prospective clinical investigations in the future. Centers that are involved in this trial will be prioritized for contracting and enrollment in the MsTR.

If any further questions or if you would like to explore joining the MsTR, <https://www.aaos.org/registries/> has additional information.

Guidelines and Evidence Based Medicine Committee – Felasfa Wodajo, MD, Chair

In January 2021, our committee started working on a methodology for producing clinical practice guidelines (CPGs). Previously, all musculoskeletal oncology practice guidelines were produced by other societies. The main requirement for this methodology is to enable us to produce high-quality CPGs, with recommendations that do not go beyond the quality of the underlying evidence. We also tailored the methodology to be appropriate for MSTs resources and the orthopedic oncology literature. We developed it in partnership with the AAOS Department of Clinical Quality and Value, the unit that produces AAOS CPGs. The methodology was completed in August. Shortly after we began soliciting volunteers for our first CPG. The topic selected was surgical management of humerus metastatic disease. It was chosen for its clinical relevance and the variability of clinical practice, which suggests an opportunity for guidelines. We also suspected there would be a limited amount of literature, which may be more appropriate for our first CPG.

This first MSTs-produced CPG is now nearing completion. Eleven workgroup members, chaired by Nicholas Tedesco and Nate Mesko, met virtually in Janu-

ary 2022 to decide on the seven clinical (“PICO”) questions to be addressed. From these PICO questions, AAOS medical librarians performed a systematic search. Then AAOS methodologists screened the identified literature for quality and applied our inclusion and exclusion criteria. Once completed, three person “PICO workgroups” reviewed the included literature and wrote the CPG recommendations. The entire workgroup reviewed, commented and eventually voted on each recommendation, completing the process in a video meeting in August. The workgroup chairs are now assembling the first draft of the CPG. This will be presented to the MSTs membership for public comment before submission to the Executive Committee for approval.

As would be expected from the paucity of high-quality literature, most important clinical questions did not have adequate evidence to make strong recommendations. However, the process went smoothly, with the large majority of workgroup members submitting very positive responses in a survey. Based on these experiences, we will be making a few minor modifications in our methodology, and should be poised to start working on our

next CPG. This will likely be on the surgical management of spinal metastases.

The GEBM committee is working on other new initiatives. These include an effort to develop structured scoring of methodologic quality of submitted Annual Meeting abstracts. Another is to produce periodic, structured, evidence reviews of new techniques that we are calling “novel practice assessments”.

This is my last update as chair. It has been a pleasure to serve the MSTs. If you have any ideas for guidelines or other quality improvement projects, please do not hesitate to reach out to [myself](#) or any GEBM committee members.

Your Purpose Is Our Passion

My3D® Personalized Pelvic Reconstruction

Helping to address the clinical challenges of complex pelvic reconstruction



Supporting Implant Fixation

BioGrip® Technology - a novel 3D-printed porous structure to support bone ingrowth

- Key studies suggest optimal pore size ranges of 350-1000µm¹⁻⁴
- Implant design options with integrated soft tissue anchor points



Reducing Complexity

Patient-matched acetabular components that eliminate some of the surgical steps required with modular off-the-shelf offerings



Delivering Personalization

Driven by speed and expertise

- Dedicated Onkos Patient Solutions Engineer
- FDA clearance that enables a 6-week delivery time

Image Transfer

Pre-operative Rendering

Anatomic Review

Instrumentation and Implant Design

My3D® Personalized Pelvic Reconstruction



1. Taniguchi, et al., Effect of pore size on bone in-growth into porous titanium implants fabricated by additive manufacturing: an in vivo experiment. *Mater Sci Eng C Mater Biol Appl.* 2016;59:690-701. 2. Dickey IA, et al. Pore size and morphology modulate strength of soft tissue in-growth into porous titanium implants. Poster presented at: 54th Annual Meeting of the Orthopaedic Research Society; San Francisco, CA; March 2-5, 2008. 3. Dickey IA, et al. Pore size modulates strength of soft-tissue in-growth and growth factor expression in novel porous titanium implants. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society; Las Vegas, NV; February 22-25, 2009. 4. Data on File. Onkos. 2022.

Contact us to learn more:

973.264.5400 | onkossurgical.com

Disclaimer: A surgeon should rely exclusively on his or her own professional medical/clinical judgment when deciding which particular product to use when treating a patient. ONKOS SURGICAL does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any ONKOS SURGICAL product. The My3D® Personalized Pelvic Reconstruction resection guides are not indicated for tumors where a specific margin is desired.

ONKOS SURGICAL and My3D are registered marks and trademarks of ONKOS SURGICAL. © 2022 ONKOS Surgical. All rights reserved. CORP 08.18.22 v0

Precision Orthopaedics

- ELEOS™ Limb Salvage Solutions
- My3D® Personalized Solutions
- GenVie® Regenerative Biologics



Thank you to our 2022 MSTs Donors!

John A. Abraham, MD
Megan E. Anderson, MD
Scot A. Brown, MD
Emily E. Carmody, MD
Mark C. Gebhardt, MD
John H. Healey, MD, FACS

Carrie L. Heincelman, MD
Susan M. McDowell, MD
Michael P. Mott, MD
Richard J. O'Donnell, MD
Rajiv Rajani, MD
Herrick J. Siegel, MD

Nicholas Tedesco, MD
Kristy L. Weber, MD
Rosana Wustrack, MD
Melissa N. Zimel, MD

*Donations processed from January 1, 2022
through October 1, 2022*

Membership Committee – Matthew R. DiCaprio, MD, Chair

The Membership Committee is actively working to enhance MSTs membership value and to attract the best and brightest in our field of musculoskeletal oncology. Thank you to our dedicated members: Robert J. Esther, Kelly Homlar, Christina Gutowski, David Greenberg and Andre Spiguel, for their service proposing ways to enhance the member experience, reviewing applications for membership, and for vetting proposed surveys to our members. We want to encourage applications for membership at all levels: from residents, candidates, to active members. For those candidate members who are eligible for active membership please consider submitting an application with our next cycle in the new year.

Within your local multi-disciplinary teams at your institutions please consider inviting a member of your team; an oncologist, radiologist and or pathologist to an upcoming meeting to expose them to our great society and try to expand our collaboration to other physicians passionate about the care of musculoskeletal tumors. We are working closely with the communications committee to update the MSTs website with useful member information, and to hear from all of you on your preferences pertaining to communication from MSTs. As our society is taking a leadership role pertaining to Orthopaedic Oncology fellowship oversight, we are working to enhance communication with all recent, current and future fellows on the society application process and value of membership.

If you have any suggestions pertaining to membership please feel free to contact me at dicaprm@amc.edu.

The Membership Committee would like to welcome the following new members who were recently approved by the Executive Committee:

If you are interested in becoming a member, or to change your current MSTs membership category, please click [here](#) to apply. The application deadline to be included in the next review is Friday, February 10, 2023

MSTs Welcomes New Members in 2022

We are very pleased to welcome the following new members who were approved for MSTs membership by the Executive Committee in March 2022.

Active Members

Anna R. Cooper, MD, MPH
Brooke M. Crawford, MD
Joseph Kuechle, MD, PhD

Candidate Members

Meredith Bartelstein, MD
Danielle S. Chun, MD
Erica Giles, MD
Gregory Y. LaChaud, MD
Karim Masrouha, MD
Shalin S. Patel, MD

Resident Members

Megan R. Hsu, MD
Kyle Walker, MD, MBA


Medtronic

Clinically significant pain relief

OPuS One clinical data on OsteoCool™ RF ablation

OsteoCool™ RF ablation demonstrated improvements in pain relief and quality of life.

- **3 days post procedure** ($P < 0.0001$)
- **Significant improvement at all visits** ($P < 0.0001$ for all visits)



Choose OsteoCool™ RF Ablation –
Meaningful pain relief when every day counts
[Medtronic.com/OpusOne](https://www.medtronic.com/OpusOne)

References

Levy J, Hopkins T, Morris J, et al. Radiofrequency ablation for the palliative treatment of bone metastases: outcomes from the multicenter OsteoCool tumor ablation post-market study (OPuS One study) in 100 patients. *J Vasc Interv Radiol.* 2020;31:1745-1752. <https://doi.org/10.1016/j.jvir.2020.07.014>

Levy J, David E, Hopkins T, et al. Radiofrequency ablation for the palliative treatment of osseous metastases: final results from a multicenter study (OPuS One). Abstract presented at the Society for Interventional Radiology Annual Scientific Meeting. Virtual. 2021.

Levy J, David E, Hopkins T, et al. Improvement in quality of life in patients treated for painful osseous metastases with radiofrequency ablation: The OPuS One Study. Abstract presented at the Society for Interventional Radiology Annual Scientific Meeting. Virtual. 2021.

Indications and Risks: The OsteoCool™ RF Ablation System is intended for ablation of benign tumors such as osteoid osteoma and for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. It is also intended for coagulation and ablation of tissue in bone during surgical procedures, including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. Risks of the system include damage to surrounding tissue through iatrogenic injury as a consequence of electrosurgery; pulmonary embolism; nerve injury including thermal injury, puncture of the spinal cord or nerve roots potentially resulting in radiculopathy, paresis, and paralysis. The OsteoCool Bone Access Kits are indicated for percutaneous access to bone.

Fellowship Committee – Raffi Avedian, MD, Chair

The Fellowship Committee is happy to announce that the new process for MSTs recognition of fellowships is underway. Briefly, programs must be MSTs recognized in order to participate in SF Match and the Central Application Service (CAS). Also, orthopaedic oncology fellows who wish to become active members of the MSTs must graduate from an MSTs recognized program. For a program to be MSTs recognized they must either be ACGME accredited or undergo an MSTs recognition application process. The purpose of this new initiative is to ensure that fellowship programs, current and future, meet a minimum standard of educational and experiential quality as they train the next generation of orthopaedic oncologists. We received seven applications for MSTs recognition this year, 1 program is actively applying for ACGME accreditation, and 12 are already ACGME accredited.

The Fellowship Committee is excited to offer several career development opportunities for MSTs members which include an Onkos sponsored travelling fellowship and

the Howard Hatcher Pathology Fellowship. The ONKOS supported travelling fellowship grant award is meant to offset the costs for a fellow enrolled in an MSTs recognized fellowship to travel to another north American fellowship program for a mutually agreed timeframe, typically 1 week, to gain clinical perspective, education, and professional connection with a program outside of their own. Depending on host institution policies and local medical licensing laws the time spent at the host institution may be an observership rather than participation in patient care. It is up to the visiting fellow and host institution to determine which type and length of activity is most appropriate. This experience may take place anytime during or up to 6 months after completion of a fellowship. We are currently accepting applications and more information and the application forms can be found on the MSTs website under the fellowship tab.

In addition, we will be accepting applications for the Hatcher Pathology Fellowship starting January 1st 2023. This fellowship

developed by Dr. Howard Hatcher's former residents is meant to enrich the career of a fellow or junior attending who aspires for an academic career in musculoskeletal oncology. Funds from the grant may be used for any opportunity the applicant feels best suits their needs and may include but are not limited to participation in the Clinician Scholar Development Program, grant writing workshop, or visitation of a renowned institution for the purpose of clinical observation, research, or scholarly study. Rather than formulate specific requirements for Fellowship opportunities, the MSTs will consider each applicant's request based on individual merit. Preference is given to early career orthopaedic surgeons and activities that in some manner involve international experience. Requirements and applications for the Fellowship can be found on the MSTs website under the Fellowship tab.

Please reach out to Fellowship Chair, Raffi Avedian at ravedian@stanford.edu with any questions. We look forward to ongoing service to the membership.

Metastatic Bone Disease Task Force Update – Felasfa Wodajo, MD, Chair

In March 2022, the Executive Committee of the MSTs voted to convene a Task Force that will develop a strategy that will drive the Society to better address the needs of patients with metastatic bone disease, as well its members, nearly all of whom devote a significant portion of their practice to treating these patients.

The call for volunteers for the MBD Task Force was met with an enthusiastic response, with nearly 30 members expressing interest. Through a blinded process, we were able to select nine at-large MSTs members to sit on the Task Force. Other members represent specific MSTs committees and the presidential line. In addition, we have recruited advisory members in adjacent specialties, including medical oncology and spine surgery. We are in the process of recruiting others in radiation oncology and interventional radiology.

The Task Force held its first virtual meeting in August. We are now in the process of forming subcommittees to address specific topics, including:

1. Disparities
2. Industry partnerships
3. Novel procedures
4. Spine surgery

In addition, these committees will be led by the corresponding MSTs committee representative

1. Annual Meeting
2. Education
3. Practice Management

We anticipate holding a second virtual meeting shortly after our Annual Meeting in December, after which we will begin the process of researching and writing our recommendations for the Society. If you have any ideas or suggestions, please

do not hesitate to [contact me](#) or any Task Force member.



Rethink desmoid tumors

Don't underestimate these unpredictable tumors and their “tendrill-like” growths¹

- Desmoid tumors can be locally invasive and painful, with “tendrill-like” growths that can threaten vital structures and compromise patients’ function and quality of life²⁻⁴
- Approximately 30% to 40% of desmoid tumors are initially misdiagnosed due to their rarity and histologic mimics¹
- There are currently **no FDA-approved treatment options** specifically indicated for desmoid tumors. **In most cases, surgery is no longer the recommended first-line treatment approach for desmoid tumors**^{1,5}

A diagnosis can raise more questions for patients than answers. SpringWorks Therapeutics is committed to helping you provide resources and information for your patients with desmoid tumors.

Visit DesmoidTumors.com/HCP for information and resources to diagnose, manage, and help guide patients with desmoid tumors.

References

1. Kasper B, Baumgarten C, Garcia J, et al. Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol.* 2017;28(10):2399-2408. 2. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. *Curr Opin Oncol.* 2017;29(4):268-274. 3. Baranov E, Hornick JL. Soft tissue special issue: fibroblastic and myofibroblastic neoplasms of the head and neck. *Head Neck Pathol.* 2020;14(1):43-58. 4. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? *Support Care Cancer.* 2019;27(3):965-980. 5. The Desmoid Tumor Working Group. The management of desmoid tumors: a joint global evidence-based consensus guideline approach for adult and pediatric patients. Accessed April 10, 2022. https://dtrf.org/wp-content/uploads/2020/02/Desmoid_Paper_2018_A4_RL_Web300-1.pdf.



Update from NOLC, BOS/ BOC Annual Meeting and Capitol Hill Day

We had a successful meeting in Washington DC in September. Drs Joel Mayerson, Matthew DiCaprio and Odion Binitie represented MSTs via BOC and BOS.

From the Academy advocacy chair,
Douglas Lundy, MD:

Our advocacy efforts have paid off in a big way. On Wednesday at 12:45 pm, *The Improving Seniors Timely Access to Care Act* (HR 3173) passed by voice vote on the House floor. AAOS was the last group to lobby Congress in favor of this bill, and our collected voices resonated. While this is a huge accomplishment, we still have an uphill battle to get this passed in the Senate, especially as we enter the mid-term elections and a condensed Senate calendar. We also built significant momentum for The Supporting Medicare Providers Act of 2022 (HR 8800), which was introduced during our day on the Hill, while also prevailing upon Congress the importance of an inflationary update to mirror other parts of Medicare. Additionally, we wanted to thank you for supporting OrthoPAC. Many legislators supportive of our priority legislation face tough re-election campaigns in November. Twenty of the cosponsors of HR 3173 are in critical races. We must make sure to keep our musculoskeletal champions in Congress, which is one of the priority charges of the OrthoPAC.

A reminder regarding the changes to AAOS Annual Meeting and Specialty Day schedule. Anchoring of Specialty day programming on Tuesday and Saturday will begin during the 2023 Annual Meeting in Las Vegas, and on Monday and Friday during the 2024 Annual Meeting in San Francisco. MSTs will be on Saturday and Friday respectively.

Below is the confirmed scheduled for both the 2023 and 2024 AAOS Annual Meetings:

AAOS 2023 Annual Meeting	
Tuesday	Saturday
ASES	AANA
Hip/AAHKS	AOSSM
Knee/AAHKS	ASSH/AAHS
LLRS	MSTS
DRC Course	OTA
	SOMOS

AAOS 2024 Annual Meeting	
Monday	Friday
Hip/AAHKS	AANA
Knee/AAHKS	AOSSM/ASES
OTA	ASSH/AAHS
	LLRS
	MSTS
	ORA
	SOMOS

Odion Binitie
BOS representative

SarcomaStrong Corner – Matthew R. DiCaprio, MD

"To be good, and to do good, is all we have to do."

– John Adams

Year after year SarcomaStrong continues to inspire an army of individuals to work collaboratively to lessen the human suffering from sarcoma. So far in 2022 we have accomplished our goals outlined in the last MSTs newsletter and continue to move the needle of progress. Our in person events in Albany, Boston, and Hamilton, Ontario on August 13, 2022 were a tremendous success. Megan Anderson and Michelle Ghert have led the charge in their communities and I am grateful for

their collaboration. Several other centers participated during our Global event dates of August 12-14 and on other dates that worked best for their communities. Notably, Rajiv Rajani at Texas Tech in El Paso with the collaboration of sarcoma survivor Shane Munoz, and Rosanna Wustrack and Melissa Zimel at UCSF. David Geller, Bang Hoang, and Rui Yang and the Montefiore community continue to organize a Knock Out Sarcoma event every June and had another successful event in 2022.



*Raise Sarcoma Awareness
Advocate for Sarcoma Families
Raise funds for Research*

We collectively raised close to \$150,000 to date in 2022, had >2000 donors and participants from 35 US states and over 14 countries. The greatest joy has been in
Continued on page 14

Delivering **Comprehensive Solutions** for **Significant Bone Loss**

**Join us at the MSTs 2022 Annual Meeting
November 30th – December 2nd.**

Hear from Dr. Lor Randall, M.D., F.A.C.S.
as he presents on the OSS™ Orthopedic Salvage System
our comprehensive modular platform,
designed for intraoperative flexibility.

Learn More



ZIMMER BIOMET

This material is intended for health care professionals. All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. Distribution to any other recipient is prohibited. For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and www.zimmerbiomet.com. Check for country product clearances and reference product specific instructions for use. ©2022 Zimmer Biomet • A0087.1-GLBL-en-Issue Date-2022-08



building collaborative relationships with passionate surgeons, oncologists, and patients around the globe. Each looking to do more for their local sarcoma communities. The human side of our field comes out at these events. Interacting with our patients outside of the office or operative suite and seeing them build friendships with other sarcoma warriors is priceless. A few more events may still pop up in 2022 to round out the year. Bryan Moon and the MD Anderson team are planning an event for Houston during a cooler time of year.

Thanks to the work of the Research committee and the SarcomaStrong grant review team under Kurt Weiss's leadership, the SarcomaStrong Research fund has supported two projects in 2022. Congratulations to Julia Visgauss, MD from Duke and Steven Thorpe, MD from UC Davis, recipients of 2022 SarcomaStrong research funding. We look forward to seeing your great work from your research teams. We are working with Tae Won Kim and the communications team to get




all research funding announcements on the MSTs webpage and all previous grant recipients recognized for their tremendous accomplishments.

Our growth and rebranding over the last year has in large part been from the hard work of several Albany Medical College students and our dedicated Board of Directors. In 2020, we started a Sarcoma Strong Service Learning Program at Albany Medical College which has been very successful and a rewarding experience for our medical students. In September we welcomed thirteen students to join the team and assist in our mission. What if we could get this to grow across North

American medical schools offering similar programs modeled after our pilot?

Please consider starting an event at your program to assist in our future growth and engagement. Another easy way to support our fundraising mission is to visit and share our merchandise shop at sarcomastrong.com/shop and purchase some SarcomaStrong swag. If you are interested in being more engaged or hosting a live or virtual event at your institution please contact me by cell 518-378-6499 or dicaprm@amc.edu.

Together We Unite the Sarcoma Fight



Musculoskeletal Tumor Society

1515 E. Woodfield Road, Suite 345 • Schaumburg, IL 60173

website: www.MSTS.org

phone: 847/698-1625 e-mail: info@msts.org